Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 3/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.34 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
| ▸ | BCHE | P06276 | 5/20 | 0.33 |
| ▸ | ACHE | P22303 | 4/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2201870 | 0.78 | KMT2A (0.35) | — | |
| SCHEMBL4947145 | 0.77 | CA2 (0.42) | CA2CA1SMN1; SMN2SIGMAR1BCHE | |
| SCHEMBL2201909 | 0.76 | CXCR4 (0.34) | — | |
| SCHEMBL2201911 | 0.76 | CXCR4 (0.34) | — | |
| SCHEMBL2204036 | 0.76 | CA2 (0.41) | CA2CA1SMN1; SMN2SIGMAR1 | |
| SCHEMBL2204041 | 0.75 | CXCR4 (0.41) | CA2CA1SMN1; SMN2SIGMAR1 | |
| SCHEMBL4947147 | 0.73 | CA2 (0.40) | CA2CA1SMN1; SMN2SIGMAR1BCHE | |
| SCHEMBL2202511 | 0.73 | CA2 (0.41) | CA2CA1SMN1; SMN2BCHEACHE | |
| SCHEMBL12426408 | 0.70 | LTA4H (0.41) | CA2CA1SMN1; SMN2BCHEACHE | |
| SCHEMBL2202381 | 0.70 | CYP1A2 (0.40) | CA2CA1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7977512-B2 | Amine derivative, and production method and use thereof | KUREHA CORPORATION (JP) | 2011-07-12 | — | — | US | disclosed |
| US-20080293951-A1 | Amin Derivative, and Production Method and Use Thereof | KUREHA CORPORATION | 2008-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293951-A1 | Amin Derivative, and Production Method and Use Thereof | BCAT2, BCAT1, MRPL9 | CA2 1761/4885CA1 3598/4885SMN1; SMN2 3667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.